Literature DB >> 34080180

Magnetic resonance imaging in neuromyelitis optica spectrum disorder.

Laura Clarke1,2, Simon Arnett1,3, Kate Lilley1,3, Jacky Liao1, Sandeep Bhuta1,4, Simon A Broadley1,3.   

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of the central nervous system (CNS) associated with antibodies to aquaporin-4 (AQP4), which has distinct clinical, radiological and pathological features, but also has some overlap with multiple sclerosis and myelin oligodendrocyte glycoprotein (MOG) antibody associated disease. Early recognition of NMOSD is important because of differing responses to both acute and preventive therapy. Magnetic resonance (MR) imaging has proved essential in this process. Key MR imaging clues to the diagnosis of NMOSD are longitudinally extensive lesions of the optic nerve (more than half the length) and spinal cord (three or more vertebral segments), bilateral optic nerve lesions and lesions of the optic chiasm, area postrema, floor of the IV ventricle, periaqueductal grey matter, hypothalamus and walls of the III ventricle. Other NMOSD-specific lesions are denoted by their unique morphology: heterogeneous lesions of the corpus callosum, 'cloud-like' gadolinium (Gd)-enhancing white matter lesions and 'bright spotty' lesions of the spinal cord. Other lesions described in NMOSD, including linear periventricular peri-ependymal lesions and patch subcortical white matter lesions, may be less specific. The use of advanced MR imaging techniques is yielding further useful information regarding focal degeneration of the thalamus and optic radiation in NMOSD and suggests that paramagnetic rim patterns and changes in normal appearing white matter are specific to MS. MR imaging is crucial in the early recognition of NMOSD and in directing testing for AQP4 antibodies and guiding immediate acute treatment decisions. Increasingly, MR imaging is playing a role in diagnosing seronegative cases of NMOSD.
© 2021 British Society for Immunology.

Entities:  

Keywords:  diagnosis; magnetic resonance imaging; multiple sclerosis; neuromyelitis optica

Mesh:

Substances:

Year:  2021        PMID: 34080180      PMCID: PMC8561702          DOI: 10.1111/cei.13630

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  163 in total

1.  Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica.

Authors:  Zhengqi Lu; Wei Qiu; Yan Zou; Kefeng Lv; Youming Long; Wenxia You; Xueping Zheng; Xueqiang Hu
Journal:  J Neurol Sci       Date:  2010-03-25       Impact factor: 3.181

2.  Brain abnormalities in neuromyelitis optica.

Authors:  Jee-Eun Kim; Sung-Min Kim; Suk-Won Ahn; Bung Chan Lim; Jong Hee Chae; Yoon-Ho Hong; Kyung-Seok Park; Jung-Joon Sung; Kwang-Woo Lee
Journal:  J Neurol Sci       Date:  2011-01-13       Impact factor: 3.181

3.  Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.

Authors:  Sean J Pittock; Brian G Weinshenker; Claudia F Lucchinetti; Dean M Wingerchuk; John R Corboy; Vanda A Lennon
Journal:  Arch Neurol       Date:  2006-07

4.  Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy.

Authors:  Sylvain Rabasté; Alvaro Cobo-Calvo; Veronica Nistiriuc-Muntean; Sandra Vukusic; Romain Marignier; François Cotton
Journal:  J Neuroradiol       Date:  2020-05-12       Impact factor: 3.447

5.  Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications.

Authors:  B F Gh Popescu; V A Lennon; J E Parisi; C L Howe; S D Weigand; J A Cabrera-Gómez; K Newell; R N Mandler; S J Pittock; B G Weinshenker; C F Lucchinetti
Journal:  Neurology       Date:  2011-03-02       Impact factor: 9.910

6.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Authors:  Sean J Pittock; Achim Berthele; Kazuo Fujihara; Ho Jin Kim; Michael Levy; Jacqueline Palace; Ichiro Nakashima; Murat Terzi; Natalia Totolyan; Shanthi Viswanathan; Kai-Chen Wang; Amy Pace; Kenji P Fujita; Róisín Armstrong; Dean M Wingerchuk
Journal:  N Engl J Med       Date:  2019-05-03       Impact factor: 91.245

7.  Brain magnetic resonance imaging abnormalities in neuromyelitis optica.

Authors:  Y Li; P Xie; F Lv; J Mu; Q Li; Q Yang; M Hu; H Tang; J Yi
Journal:  Acta Neurol Scand       Date:  2008-03-31       Impact factor: 3.209

8.  A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort.

Authors:  Kavita Sohan Barhate; Malti Ganeshan; Bhim Sen Singhal
Journal:  Ann Indian Acad Neurol       Date:  2014-01       Impact factor: 1.383

9.  Optic Perineuritis and Its Association With Autoimmune Diseases.

Authors:  Hongyang Li; Hang Zhou; Jiao Sun; Huihui Wang; Yanling Wang; Zhenchang Wang; Jing Li
Journal:  Front Neurol       Date:  2021-01-29       Impact factor: 4.003

10.  Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study.

Authors:  Nasrin Asgari; Hanne Pernille Bro Skejoe; Soeren Thue Lillevang; Troels Steenstrup; Egon Stenager; Kirsten Ohm Kyvik
Journal:  BMC Neurol       Date:  2013-04-08       Impact factor: 2.474

View more
  2 in total

Review 1.  Magnetic resonance imaging in neuromyelitis optica spectrum disorder.

Authors:  Laura Clarke; Simon Arnett; Kate Lilley; Jacky Liao; Sandeep Bhuta; Simon A Broadley
Journal:  Clin Exp Immunol       Date:  2021-07-06       Impact factor: 4.330

2.  Imaging immune responses in neuroinflammatory diseases.

Authors:  Sandra Amor; Erik Nutma; David Owen
Journal:  Clin Exp Immunol       Date:  2021-12       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.